Latest filings (excl ownership)
15-15D
Suspension of duty to report
1 Apr 21
RW
Registration withdrawal request
29 Mar 21
6-K
Emerald Health Therapeutics Establishes Partnership with Spanish Greenhouse Grower for GMP-Certified Cannabis
17 Mar 21
6-K
Emerald Health Therapeutics Announces Intention to List on Canadian Securities Exchange
10 Mar 21
6-K
Current report (foreign)
18 Feb 21
6-K
Emerald Health Therapeutics Receives $20.5M Payment from Village Farms and Outlines Growth Plans
9 Feb 21
6-K
Current report (foreign)
5 Feb 21
6-K
Current report (foreign)
13 Jan 21
6-K
Emerald Health Therapeutics' Partner STENOCARE Makes First Delivery of Medical Cannabis Oil to Swedish Patients
29 Dec 20
6-K
Current report (foreign)
17 Dec 20
6-K
Emerald Health Therapeutics Terminates Agreement for Sale of Quebec Cannabis Business
4 Dec 20
6-K
Emerald Health Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update
2 Dec 20
6-K
Condensed Interim Consolidated Financial Statements
30 Nov 20
6-K
Emerald Health Therapeutics Announces Full Prepayment of Convertible Debentures
24 Nov 20
6-K
Emerald Health Therapeutics Completes Sale of Pure Sunfarms Interest and Achieves Pivotal Milestone in Transforming its Business
2 Nov 20
6-K
Emerald Shareholders Vote in Favour of Sale of Pure Sunfarms
29 Oct 20
6-K
Emerald Health Therapeutics Launches Flavoured Cannabis Oils, Expanding SYNCTM Product Line
19 Oct 20
6-K
Emerald Health Therapeutics Receives Standard Processing License for Richmond, BC Greenhouse Facility
13 Oct 20
6-K
Emerald Health Therapeutics Closes Shares for Debt Transaction
17 Sep 20
6-K
Emerald Health Therapeutics and STENOCARE Receive Swedish Medicines Agency Approval to Provide Medical Cannabis Oil to Patients
10 Sep 20
6-K
Emerald Health Therapeutics Enters into Share Purchase Agreement for Sale of Pure Sunfarms
8 Sep 20
6-K
Emerald Health Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update
1 Sep 20
6-K
Report of Foreign Private Issuer for the Month of August, 2020
31 Aug 20
6-K
Current report (foreign)
31 Aug 20
6-K
Emerald Health Therapeutics' Pure Sunfarms Joint Venture Begins Shipping Cannabis 2.0 Products and Bottled Oils
25 Aug 20
6-K
Emerald Health Therapeutics Announces Shares for Debt Transaction
21 Aug 20
6-K
Emerald Health Therapeutics Announces New At-the-Market Equity Program
13 Aug 20
6-K
Emerald Health Therapeutics Reports Pure Sunfarms Second Quarter 2020 Financial Results
13 Aug 20
6-K
Emerald Health Therapeutics Announces Stock Option Grant
6 Aug 20
20-F/A
2019 FY
Annual report (foreign) (amended)
3 Aug 20
6-K
Emerald Health Therapeutics and Quinto Resources Enter into Share Purchase Agreement for Sale of Québec Cannabis Business
31 Jul 20
6-K
Emerald Health Therapeutics’ Pure Sunfarms Joint Venture Begins Shipping Branded Products to Manitoba
24 Jul 20
6-K
Emerald Health Therapeutics Terminates Consulting and Loan Agreements
15 Jul 20
6-K
Emerald Health Therapeutics Announces Completion of Accordion Provision of Pure Sunfarms’ Credit Facility
1 Jul 20
6-K
Emerald Health Therapeutics’ Joint Venture Pure Sunfarms’ Branded Products Ship to Saskatchewan and are Approved in Manitoba
25 Jun 20
6-K
Emerald Health Therapeutics’ Verdélite Launches Souvenir™ Cannabis Brand in Québec
23 Jun 20
6-K
Emerald Health Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update
19 Jun 20
6-K
Condensed Interim Consolidated Financial Statements
18 Jun 20
6-K
Current report (foreign)
11 Jun 20
20-F
2019 FY
Annual report (foreign)
10 Jun 20
Latest ownership filings
No filings